Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-06-03 Remuneration Information
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Block listing Interim Review
Remuneration Information Classification · 99% confidence The document is explicitly titled 'BLOCK LISTING SIX MONTHLY RETURN' and provides detailed figures regarding the balance of unallotted securities under various share option plans over a specific period (1 DECEMBER 2023 to 31 MAY 2024). This type of filing, which reports on the status of securities reserved for employee share schemes, is a specific regulatory disclosure. While it relates to share capital changes, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a routine regulatory return provided to the exchange via RNS. Given the specific nature of reporting on block listings and option plans, and its origin as an RNS filing, it fits best under the general 'Regulatory Filings' category (RNS) as there is no specific code for a 'Block Listing Return'. It is not a comprehensive financial report (10-K, IR) or a management/board change announcement.
2024-06-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the RNS Number (6859Q) and explicitly states it is providing a notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 regarding 'Voting rights and capital'. It details the total number of voting rights as of May 31, 2024. This type of mandatory regulatory disclosure concerning the total number of shares with voting rights, often used as a denominator for shareholder notifications, fits best under the general regulatory announcement category, RNS, as it is not a specific financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or SHA). Although it relates to capital structure, its primary function here is regulatory disclosure via the RNS system.
2024-06-03 English
TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the recommendation for approval of Tagrisso plus chemotherapy in the EU, including clinical trial results, drug information, and company background. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about the company's product development and regulatory status. The document length is 13,329 characters, indicating it is a substantive report rather than a brief announcement. Since Form 6-K filings are typically categorized as Regulatory Filings (RNS) in this classification scheme, and the content aligns with this, the appropriate classification is Regulatory Filings (RNS).
2024-06-03 English
Tagrisso plus chemo recommended for approval in EU
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 7488Q' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority to act as a Primary Information Provider. The content itself is a press release announcing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding AstraZeneca's drug Tagrisso. This type of announcement, which disseminates material, time-sensitive information via an official regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). It is a general regulatory announcement.
2024-06-03 English
DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed clinical trial results and regulatory update information about a drug (datopotamab deruxtecan) for nonsquamous non-small cell lung cancer. The document is an announcement of clinical trial results and regulatory progress, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis. It is not a call transcript, management report, or governance information. The document is a regulatory filing providing material information about the company's drug development and regulatory status. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (13,489 characters) and content confirm it is not a brief announcement but a substantive regulatory update, yet it is not a financial report or earnings release.
2024-05-28 English
Dato-DXd improved OS in nonsquamous lung cancer
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 9394P' and is dated May 28, 2024. It contains a headline about clinical trial results ('Datopotamab deruxtecan showed clinically meaningful overall survival improvement...') and includes quotes from company executives and detailed scientific/trial information. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a regulatory news service announcement, which falls under the general category of Regulatory Filings (RNS) or potentially an Earnings Release (ER) if it were purely financial results. Since this is a specific, material announcement about clinical trial data that supports regulatory applications, and it is distributed via the RNS system, RNS is the most appropriate general classification for this type of market-sensitive disclosure that isn't a full report (like 10-K or IR) or a dedicated earnings release (ER). Given the options, RNS serves as the best fit for a general regulatory news wire announcement.
2024-05-28 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.